Low dose of human PTH(1-34) improved tibial subcortical bone mass without further cortical bone loss in adult intact beagles

1998 ◽  
Vol 16 (2) ◽  
pp. 96-99 ◽  
Author(s):  
Liu Zhang ◽  
Hideaki E. Takahashi ◽  
Tatsuhiko Tanizawa ◽  
Naoto Endo ◽  
Noriaki Yamamoto ◽  
...  
Maturitas ◽  
1991 ◽  
Vol 13 (1) ◽  
pp. 85
Author(s):  
E.C.H. Van Beresteijn ◽  
M.A. Van't Hof ◽  
H. De Waard ◽  
J.A. Raymakers ◽  
S.A. Duursma

Bone ◽  
1990 ◽  
Vol 11 (1) ◽  
pp. 7-13 ◽  
Author(s):  
E.C.H. van Beresteijn ◽  
M.A. van't Hof ◽  
H. de Waard ◽  
J.A. Raymakers ◽  
S.A. Duursma

2020 ◽  
Vol 107 (2) ◽  
pp. 170-179 ◽  
Author(s):  
Antoine Farley ◽  
Vasily Gnyubkin ◽  
Arnaud Vanden-Bossche ◽  
Norbert Laroche ◽  
Mieke Neefs ◽  
...  

2021 ◽  
Author(s):  
Filipa Ponte ◽  
Ha-Neui Kim ◽  
Aaron Warren ◽  
Srividhya Iyer ◽  
Li Han ◽  
...  

The protective effect of estrogens against cortical bone loss is mediated via direct actions on mesenchymal lineage cells, but functional evidence for the precise molecular mechanism(s) and the mediators of these effects has only recently began to emerge. We report that the matrix metalloproteinase 13 (MMP-13) is the highest up-regulated gene in calvaria or bone marrow cells from mice lacking the estrogen receptor (ER) alpha in osteoprogenitors. We, therefore, generated mice with conditional Mmp-13 deletion in Prrx1 expressing cells ( Mmp-13 ?Prrx1 ) and compared the effect of estrogen deficiency on their bone phenotype to that of control littermates ( Mmp-13 f/f ). Femur and tibia length was decreased in sham-operated Mmp-13 ?Prrx1 mice as compared to Mmp1 3 f/f . Cortical thickness and trabecular bone volume in the femur and tibia were increased and osteoclast number at the endocortical surfaces was decreased in the sham-operated female Mmp13 ?Prrx1 mice; whereas bone formation rate was unaffected. Ovariectomy (OVX) caused a decrease of cortical thickness in the femur and tibia of Mmp-13 f/f control mice. This effect was attenuated in the Mmp-13 ? Prrx1 mice; but the decrease of trabecular bone caused by OVX was not affected. These results reveal that mesenchymal cell–derived MMP-13 regulates osteoclast number, bone resorption, and bone mass. We have recently reported that the loss of cortical, but not trabecular bone, caused by OVX is also attenuated in Cxcl12 ?Prrx1 mice. Together with the present report, this functional genetic evidence provides proof of principle that increased production of mesenchymal cell-derived factors, such as CXCL12 and MMP-13, are important mediators of the adverse effect of estrogen deficiency on cortical, but not trabecular, bone. Therefore, the mechanisms responsible for the protective effect of estrogens on these two major bone compartments are different.


2018 ◽  
Vol 11 (4) ◽  
pp. 1145-1154 ◽  
Author(s):  
Nima Montazeri-Najafabady ◽  
Younes Ghasemi ◽  
Mohammad Hossein Dabbaghmanesh ◽  
Pedram Talezadeh ◽  
Farhad Koohpeyma ◽  
...  

JCI Insight ◽  
2020 ◽  
Vol 5 (19) ◽  
Author(s):  
Ha-Neui Kim ◽  
Jinhu Xiong ◽  
Ryan S. MacLeod ◽  
Srividhya Iyer ◽  
Yuko Fujiwara ◽  
...  

2013 ◽  
Vol 27 (1) ◽  
pp. 34-41 ◽  
Author(s):  
Hassan R. Mir ◽  
Ruxi C. Marinescu ◽  
Haden Janda ◽  
Thomas A. Russell

2018 ◽  
Vol 238 (1) ◽  
pp. 13-23 ◽  
Author(s):  
Thomas Funck-Brentano ◽  
Karin H Nilsson ◽  
Robert Brommage ◽  
Petra Henning ◽  
Ulf H Lerner ◽  
...  

WNT signaling is involved in the tumorigenesis of various cancers and regulates bone homeostasis. Palmitoleoylation of WNTs by Porcupine is required for WNT activity. Porcupine inhibitors are under development for cancer therapy. As the possible side effects of Porcupine inhibitors on bone health are unknown, we determined their effects on bone mass and strength. Twelve-week-old C57BL/6N female mice were treated by the Porcupine inhibitors LGK974 (low dose = 3 mg/kg/day; high dose = 6 mg/kg/day) or Wnt-C59 (10 mg/kg/day) or vehicle for 3 weeks. Bone parameters were assessed by serum biomarkers, dual-energy X-ray absorptiometry, µCT and histomorphometry. Bone strength was measured by the 3-point bending test. The Porcupine inhibitors were well tolerated demonstrated by normal body weight. Both doses of LGK974 and Wnt-C59 reduced total body bone mineral density compared with vehicle treatment (P < 0.001). Cortical thickness of the femur shaft (P < 0.001) and trabecular bone volume fraction in the vertebral body (P < 0.001) were reduced by treatment with LGK974 or Wnt-C59. Porcupine inhibition reduced bone strength in the tibia (P < 0.05). The cortical bone loss was the result of impaired periosteal bone formation and increased endocortical bone resorption and the trabecular bone loss was caused by reduced trabecular bone formation and increased bone resorption. Porcupine inhibitors exert deleterious effects on bone mass and strength caused by a combination of reduced bone formation and increased bone resorption. We suggest that cancer targeted therapies using Porcupine inhibitors may increase the risk of fractures.


2018 ◽  
Vol 29 (1) ◽  
pp. 73-81 ◽  
Author(s):  
Francisco Curate ◽  
Andreia Perinha ◽  
Ana Maria Silva ◽  
Eugénia Cunha ◽  
Cláudia Umbelino ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document